Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma

Background: Chemotherapy (chemo) combined with an immune checkpoint inhibitor (ICI) or dual ICI therapy with nivolumab and ipilimumab (nivo + ipi) is the standard first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). In this study, we evaluated real-world clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Tamba, K. Chin, H. Osumi, M. Ogura, S. Fukuoka, S. Udagawa, K. Shimozaki, K. Yoshino, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, A. Ooki
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
esophageal cancer
esophageal squamous cell carcinoma
chemotherapy
immunotherapy
early tumor shrinkage
depth of response
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819825000408
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items